Review of zolmitriptan and its clinical applications in migraine

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 993-1005

  Dowson, Andrew J ^a   Charlesworth, Bruce ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical efficacy; Migraine; Tolerability; Zolmitriptan

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; ASTOCOP; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE; FLUVOXAMINE; FROVATRIPTAN; HYDROCHLOROTHIAZIDE; MONOAMINE OXIDASE A INHIBITOR; NARATRIPTAN; NORZOLMITRIPTAN; PARACETAMOL; PIZOTIFEN; PLACEBO; PROPRANOLOL; QUINOLONE DERIVATIVE; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN; ZOMIG INSTANT; ZOMIG ZIP; ZOMIGON RAPIMELT; ZOMIGRAPIMELT; HTR1B PROTEIN, HUMAN; OXAZOLIDINONE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TRYPTAMINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL STUDY; CLINICAL TRIAL; CLUSTER HEADACHE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPTIC AURA; HUMAN; INCIDENCE; MENSTRUATION; MIGRAINE; NAUSEA; NONHUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; RECURRENT DISEASE; SOMNOLENCE; TABLET DISINTEGRATION; TACHYPHYLAXIS; THROAT DISEASE; VERTIGO; XEROSTOMIA; DRUG EFFECT; DRUG INTERACTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMAN; MIGRAINE; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; HUMANS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; TRYPTAMINES;

EID: 0035987755     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.993     Document Type: Article

References (83)

1. An update on the epidemiology of migraine
2. Relationship of headache to the phase of the menstrual cycle among young women: A daily diary study
3. Migraine in the United States: A review of epidemiology and health care use
4. Economic and social impact of migraine
5. Measuring the functional status and well being of patients with migraine headache
6. The burden of migraine. A review of cost to society
7. Migraine patients experience poorer subjective well being/quality of life even between attacks
8. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration
9. Medical consultation for migraine: Results from the American Migraine Study
10. A study of migraine and its effects in a working population
11. Epidemiology of migraine in Japan
12. Patterns of healthcare utilisation for migraine in England
13. The diagnosis of headache in primary care: Factors in the agreement of clinical and standardised diagnosis
14. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: A Canadian population survey
15. Medication patterns of recurrent headache sufferers: A community study
16. Information about migraine disability influences physicians perceptions of illness severity and treatment
17. Stratified care versus step care strategies for migraine
18. HIT-6 scores discriminate among headache sufferers differing in headache associated workplace productivity loss
19. Historical background
20. Spreading depression of activity in cerebral cortex
21. Cerebral blood flow in migraine and spreading depression
22. Current concepts of migraine pathogenesis
23. The pharmacology of ergotamine and dihydroergotamine
24. Clinical pharmacokinetics of ergotamine in migraine and cluster headache
25. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine
26. Pharmacokinetics (PK) or oral sumatriptan in migraine patients during an attack and while painfree
27. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
28. Subcutaneous sumatriptan during the migraine aura
29. Would any acute treatment for migraine demonstrate recurrence?
30. The effect of subcutaneous sumatriptan (GR43175) on central haemodynamics and the coronary circulation
31. Sumatriptan in the clinical practice: A 2-year review of 453 migraine patients
32. Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: A multi-centre, double-blind, placebo-controlled dose-range-finding study
33. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
34. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine
35. Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence
36. The clinical efficacy of zolmitriptan
37. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
38. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study
39. Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: Discovery of compounds with potential anti-migraine properties
40. Preclinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5-HT1B/1D agonist for migraine
41. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D partial agonist, 311C90 (zolmitriptan)
42. Preclinical comparative studies on the sympatholytic effects of 5-HT1D receptor agonists in vivo
43. The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan (311C90) in healthy volunteers
44. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: A double-blind, placebo-controlled study
45. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
46. The mode of action of sumatriptan is vascular? A debate
47. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system
48. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
49. The trigeminovascular system and migraine: Studies characterising cerebrovascular and neuropeptide changes seen in humans and cats
50. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT) 1B/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine?
51. [3H]311C90 binding sites in cat brain stem: Implications for migraine treatment
52. Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat
53. Effects of zolmitriptan (zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine
54. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: Demonstration of a central effect for the 5-HT1B/1D agonist zolmitriptan (311C90, Zomig)
55. Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers
56. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: Results of a placebo-controlled study in healthy volunteers
57. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers
58. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy volunteers
59. The clinical pharmacokinetics of zolmitriptan
60. Determination of the human hepatic cytochrome P450 isoenzymes involved in zolmitriptan and N-desmethyl zolmitriptan metabolism in vitro
61. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90)
62. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers
63. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)
64. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period
65. A comparison of the pharmacokinetics and tolerability profile of zolmitriptan in adolescents and adults
66. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D agonist zolmitriptan in healthy young and elderly men and women
67. No need to adjust the dose of 311C90 (zolmitriptan), a novel antimigraine treatment, in patients with renal failure not requiring dialysis
68. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan
69. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
70. 311C90, a new central and peripherally acting 5-HT 1D receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study
71. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine
72. Zolmitriptan, a 5-HT 1B/1D receptor agonist for the acute oral treatment of migraine: A multi-centre, dose-range finding study
73. 1B/1D agonist: An overview of efficacy
74. Oral zolmitriptan is effective in the acute treatment of cluster headache
75. Zolmitriptan provides consistent migraine relief when used in the long term
76. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan
77. A long-term study to maximise migraine relief with zolmitriptan
78. The triptans - A summary
79. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders?
80. Migraine symptoms: Results of a survey of self-reported migraineurs
81. Consistency of meaningful migraine relief (MMR) and quality of life in migraine patients receiving long-term treatment with 'Zomig'
82. Efficacy of zolmitriptan nasal spray in mild, moderate and severe migraine: Relationship to timing of dosing
83. Clinical pharmacokinetics of the triptans: What are the important clinical issues?